[PRNewswire] AGC Biologics Announces the Expansion of Their Cell and Gene
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"I'm very pleased that we'll be able to offer our current and future cell and gene therapy customers even more of what they need from our Milan facility," says AGC Biologics Chief Business Officer, Mark Womack. "This is but one of the important steps we are taking to ensure we keep pace with the evolving needs of the market."
"This investment is part of our global cell and gene therapy expansion plan in Europe, Asia and the US," says AGC Biologics Chief Executive Officer, Patricio Massera. "All of our innovation and expansion is focused on the needs of our partners and the patients they serve. I look forward to announcing additional expansion plans soon."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Therapy Facility in Milan, Italy
(SEATTLE, March 3, 2021 PRNewswire=연합뉴스) AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence in Milan, to increase capacities and implement viral vector suspension capabilities.
With this expansion, AGC Biologics will add two additional floors to the suite and install additional equipment on the current floor. The new facilities are scheduled to begin full operation in 2022.
"I'm very pleased that we'll be able to offer our current and future cell and gene therapy customers even more of what they need from our Milan facility," says AGC Biologics Chief Business Officer, Mark Womack. "This is but one of the important steps we are taking to ensure we keep pace with the evolving needs of the market."
"This investment is part of our global cell and gene therapy expansion plan in Europe, Asia and the US," says AGC Biologics Chief Executive Officer, Patricio Massera. "All of our innovation and expansion is focused on the needs of our partners and the patients they serve. I look forward to announcing additional expansion plans soon."
The expansion comes less than one year following AGC's successful acquisition and integration of the former MolMed S.p.A. facilities. The Milan site was the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has unique commercial manufacturing experience, with two cell & gene therapy products. AGC Biologics is now one of the very few CDMO's in the world offering both plasmid production and end-to-end cell and gene therapy services.
About AGC Biologics:
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to deliver the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our global network spans the U.S., Europe and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 1,600 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients' most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.
Logo - https://mma.prnewswire.com/media/624983/AGC_Biologics_logo_Logo.jpg
Source: AGC Biologics
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- '尹대통령 재의 요구' 채상병특검법, 국회 재표결 거쳐 폐기(종합) | 연합뉴스
- 민주유공자·양곡법 등 7개 쟁점법안 본회의 상정…野 단독표결 | 연합뉴스
- UAE 대통령 첫 국빈 방문…공군 전투기 4대 호위 비행 | 연합뉴스
- 사망 훈련병에 얼차려 시킨 중대장…과실치사·가혹행위죄 수사 | 연합뉴스
- 복지부, 전공의 '복귀 여부' 상담결과 제출기한 31일로 연장 | 연합뉴스
- 21년뒤 모든 시도 출생아
- 김호중 소속사 사실상 폐업수순…75억 투자한 카카오엔터도 타격 | 연합뉴스
- 합참 "북 정찰위성 발사 실패 엔진 연소 계통 문제로 추정" | 연합뉴스
- "북, 한일중 공동선언 반발 담화에서 中에 불만 우회표출"(종합) | 연합뉴스
- 집중관리 7대 생필품 중 계란·설탕 등 5개품목 가격 올라 | 연합뉴스